Tag - UBX

Developments

UNITY posts positive Phase 1 data in advanced vascular eye disease

UNITY Biotechnology (NASDAQ:UBX) announced positive 24-week data from its Phase 1 single ascending dose safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related...

November 9, 2021

Feature

UNITY Biotechnology developing therapeutics to slow, halt or reverse diseases of aging

UNITY Biotechnology’s (NASDAQ:UBX) current focus is on developing medicines to selectively eliminate or modulate senescent cells and to provide transformative benefit in age-related ophthalmologic and neurologic...

September 14, 2021

Developments

UNITY Biotech posts positive Phase 1 data in advanced vascular eye disease

UNITY Biotechnology (NASDAQ:UBX) announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related macular degeneration (AMD) for...

July 6, 2021

Markets

HCW starts UNITY Biotechnology at buy; PT $12

H.C. Wainwright launched coverage of UNITY Biotechnology (NASDAQ:UBX) with a “buy” rating and $12 price target. The stock closed at $4.56 on June 4. UNITY is focusing on therapeutics addressing diseases of aging, while...

June 7, 2021

Tag - UBX

UNITY posts positive Phase 1 data in advanced vascular eye disease

UNITY Biotechnology developing therapeutics to slow, halt or reverse diseases of aging

UNITY Biotech posts positive Phase 1 data in advanced vascular eye disease

HCW starts UNITY Biotechnology at buy; PT $12

General

More